(TheNewswire)
Winnipeg – TheNewswire- [April 2nd, 2024]. Cytophage Technologies Ltd.( TSXV:CYTO ) (“ Cytophage ” or the “Company”) is pleasedto provide an interim update on the recently completed human trial at TheOttawa Hospital where Cytophage bacteriophages were used to treat a patient with anantibiotic-resistant prosthetic joint infection (see press release from March 1st,2024 ). The patient had previously undergone 15surgeries and was facing the potential amputation of her leg at thewaist. She was treatedwith Cytophage phages for several weeks, via both direct injection andthrough an IV line, and the Company is happy to report that according to her physician, infectious diseases clinician-scientistDr. Marisa Azad (Principal Investigator), hercondition is steadily improving with inflammation in her bodydecreasing.
Asthis is the first time a joint replacement infection has been treatedwith a bacteriophage in Canada, this landmark treatment has caught theattention of national news media with both CTV and CBC reporting on the phage trial in severalsegments. Media segments published to dateinclude:
-
CBC The National : “Experimental treatment using viruses helps woman avoidamputation”
-
CTV National News :‘Phage’ Therapy in Canada
-
CBC News : 'This was my last resort,' Ottawa-areawoman says of experimental phage therapy to treatinfection
-
CTV Winnipeg : 'Thisis why we're here': A Winnipeg biotech company's role in a newtreatment used in Canada
Dr. Azad received special approval fromHealth Canada for this single subject clinical trial. Cytophage isexpecting to share additionalinformation on this trial with the public as permitted .
Cytophage CEO Dr. Steven Theriault commented: “It hastruly been a momentous 2024 for Cytophage.W e are incredibly proud of our team who has beenable to develop and provide this therapy. Now that this trial isgaining so much attention from the news media, there is a much largerspotlight on Cytophage, which became the first Canadian phage company to gopublic.”
In addition to the recent media coverage on Cytophage,CEO Dr. Theriault continues to be a leading voice on bacteriophageapplications within the scientific community. At an AMR Workshop onApril 1st at the 2024 World Vaccine Congress in Washington, DC, Dr.Theriault presented on the topic “The application of phages to treatbacterial infections”. Cytophage is the only publicly traded bacteriophage company in NorthAmerica with a stated focus on bacteriophage solutions for both animalhealth and human health.
For further information pleasecontact:
Heather Medwick
Chief Operating Officer
heather@cytophage.com
431 388 8873
Cytophage Investor Alerts: https://cytophage.com/subscribe/
About CytophageTechnologies
Cytophage Technologies ( TSXV:CYTO ) is apioneering biotechnology company dedicated to bacteriophage research,product development and commercialization. Committed to addressing theglobal challenge of antibiotic resistance, Cytophage advancesinnovative products that harness the power ofbacteriophages to combat bacterial infections affecting human health,animal health, and food security.
Cautionary Statement onForward-Looking Information
This news release contains “forward-lookinginformation” and “forward-looking statements” (collectively,“forward-looking statements”) within the meaning of the applicableCanadian securities legislation. All statements, other than statementsof historical fact, are forward-looking statements and are based onexpectations, estimates and projections as at the date of this newsrelease. Any statement that involves discussions with respect topredictions, expectations, beliefs, plans, projections, objectives,assumptions, future events or performance (often but not always usingphrases such as “expects”, or “does not expect”, “isexpected”, “anticipates” or “does not anticipate”,“plans”, “budget”, “scheduled”, “forecasts”,“estimates”, “believes” or “intends” or variations of suchwords and phrases or stating that certain actions, events or results“may” or “could”, “would”, “might” or “will” betaken to occur or be achieved) are not statements of historical factand may be forward-looking statements. Forward-looking statementsinvolve known and unknown risks, uncertainties and other factors whichmay cause the actual results, performance or achievements of Cytophageto be materially different from any future results, performance orachievements expressed or implied by the forward-looking statements.Factors that could cause actual results to differ materially fromthose anticipated in these forward-looking statements are
described under the caption “Risk Factors” inCytophage’s Filing Statement dated January 30, 2024, which isavailable for view on SEDAR+ at www.sedarplus.ca. These risks includebut are not limited to, the risks associated with the bacteriophageindustry, such as operational risks in development or capitalexpenditures, the uncertainty of extensive regulatory approvalrequirements, government regulations, protection of intellectualproperty, product liability and rapid technological advancements.Forward-looking statements contained herein are made as of the date ofthis press release, and Cytophage disclaims, other than as required bylaw, any obligation to update any forward-looking statements whetheras a result of new information, results, future events, circumstances,or if management’s estimates or opinions should change, orotherwise. There can be no assurance that forward-looking statementswill prove to be accurate, as actual results and future events coulddiffer materially from those anticipated in such statements.Accordingly, the reader is cautioned not to place undue reliance onforward-looking statements.
Neither the TSXV nor its RegulationServices Provider (as that term is defined in the policies of theTSXV) accepts responsibility for the adequacy or accuracy of this newsrelease.
Copyright (c) 2024 TheNewswire - All rights reserved.